Use of posaconazole in the treatment of invasive fungal&#160; infections (Q37810083)

23 August 2017

title

Use of posaconazole in the treatment of invasive fungal infections (English)

1 reference

23 August 2017

1

Aneesh K Mehta

1 reference

23 August 2017

Amelia A Langston

2

1 reference

23 August 2017

publication date

1 December 2009

1 reference

Expert Review of Hematology

23 August 2017

published in

1 reference

23 August 2017

volume

2

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

619-630

1 reference

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

23 August 2017

cites work

1 reference

A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

21 January 2018

1 reference

Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients

21 January 2018

1 reference

Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors

21 January 2018

1 reference

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

21 January 2018

Emerging fungal diseases

1 reference

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

Posaconazole : a review of its use in the prophylaxis of invasive fungal infections

21 January 2018

1 reference

Posaconazole: an oral triazole with an extended spectrum of activity

21 January 2018

1 reference

Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.

21 January 2018

1 reference

Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent

21 January 2018

1 reference

Posaconazole: a broad-spectrum triazole antifungal

21 January 2018

1 reference

Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds

21 January 2018

1 reference

Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding.

21 January 2018

1 reference

Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

21 January 2018

1 reference

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

21 January 2018

1 reference

Disposition of posaconazole following single-dose oral administration in healthy subjects

21 January 2018

1 reference

Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease

21 January 2018

1 reference

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

21 January 2018

1 reference

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

21 January 2018

1 reference

Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects

21 January 2018

1 reference

Posaconazole concentrations in the central nervous system

21 January 2018

1 reference

Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men

21 January 2018

1 reference

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

21 January 2018

1 reference

Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers

21 January 2018

1 reference

The effect of gastric Acid on the absorption of posaconazole

21 January 2018

1 reference

Omeprazole significantly reduces posaconazole serum trough level

21 January 2018

1 reference

Posaconazole plasma concentrations in juvenile patients with invasive fungal infection

21 January 2018

1 reference

Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers

21 January 2018

1 reference

Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin

21 January 2018

1 reference

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

21 January 2018

1 reference

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

21 January 2018

1 reference

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

21 January 2018

1 reference

Posaconazole-increased vincristine neurotoxicity in a child: a case report

21 January 2018

1 reference

Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients

21 January 2018

1 reference

Posaconazole: a new oral antifungal agent with an expanded spectrum of activity

21 January 2018

1 reference

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

21 January 2018

1 reference

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

21 January 2018

1 reference

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

21 January 2018

1 reference

In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest

21 January 2018

1 reference

Synergistic effect of posaconazole and caspofungin against clinical zygomycetes

21 January 2018

1 reference

Issues in antifungal susceptibility testing

21 January 2018

1 reference

Clinical relevance of resistance to antifungals.

21 January 2018

1 reference

Determination of in vitro susceptibility of ocular Fusarium spp. isolates from keratitis cases and comparison of Clinical and Laboratory Standards Institute M38-A2 and E test methods

21 January 2018

1 reference

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

21 January 2018

1 reference

Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo

21 January 2018

1 reference

Efficacy of posaconazole in a murine model of central nervous system aspergillosis

21 January 2018

1 reference

Antifungal therapy of murine Aspergillus terreus infection

21 January 2018

1 reference

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories

21 January 2018

1 reference

Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection

21 January 2018

1 reference

Efficacy of SCH56592 in a rabbit model of invasive aspergillosis

21 January 2018

1 reference

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

21 January 2018

1 reference

Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

21 January 2018

1 reference

Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species

21 January 2018

1 reference

Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model

21 January 2018

1 reference

Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model

21 January 2018

1 reference

In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model

21 January 2018

1 reference

Activity of posaconazole in treatment of experimental disseminated zygomycosis.

21 January 2018

1 reference

Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays

21 January 2018

1 reference

Posaconazole therapy of disseminated phaeohyphomycosis in a murine model

21 January 2018

1 reference

Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole

21 January 2018

1 reference

SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei")

21 January 2018

1 reference

Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana

21 January 2018

1 reference

Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans

21 January 2018

1 reference

Interactions of posaconazole and flucytosine against Cryptococcus neoformans

21 January 2018

1 reference

In vitro and in vivo activities of posaconazole against Coccidioides immitis

21 January 2018

1 reference

Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice

21 January 2018

1 reference

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

21 January 2018

1 reference

Aspergillosis. Pathogenesis, clinical manifestations, and therapy

21 January 2018

1 reference

Current approaches to diagnosis and treatment of invasive aspergillosis

21 January 2018

1 reference

Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.

21 January 2018

1 reference

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management

21 January 2018

1 reference

Epidemiology and outcome of zygomycosis: a review of 929 reported cases

21 January 2018

1 reference

Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae

21 January 2018

1 reference

Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer

21 January 2018

1 reference

Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders

21 January 2018

1 reference

Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients

21 January 2018

1 reference

Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases

21 January 2018

1 reference

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

21 January 2018

1 reference

Posaconazole as salvage therapy for zygomycosis

21 January 2018

1 reference

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

21 January 2018

1 reference

Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer

21 January 2018

1 reference

Fusarium infection in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

Fusarium infections in immunocompromised patients

21 January 2018

1 reference

Changing epidemiology of systemic fungal infections.

21 January 2018

1 reference

Binary culture biofilm formation by Stenotrophomonas maltophilia and Fusarium oxysporum

21 January 2018

1 reference

Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery

21 January 2018

1 reference

Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection.

21 January 2018

1 reference

Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex

21 January 2018

1 reference

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

21 January 2018

1 reference

Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century

21 January 2018

1 reference

Refractory coccidioidomycosis treated with posaconazole

21 January 2018

1 reference

Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis

21 January 2018

1 reference

In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi

21 January 2018

1 reference

In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi

21 January 2018

1 reference

Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B.

21 January 2018

1 reference

Treatment of Scedosporium apiospermum brain abscesses with posaconazole

21 January 2018

1 reference

Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients

21 January 2018

1 reference

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection

21 January 2018

1 reference

Triazole-resistant candidaemia following posaconazole exposure

21 January 2018

1 reference

Posaconazole therapeutic drug monitoring: a reference laboratory experience

21 January 2018

1 reference

Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation

21 January 2018

1 reference

27 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1086/506617

Identifiers

DOI

10.1586/EHM.09.46

1 reference

23 August 2017

1 reference